Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.0052W HIGH $2.23
Volume
129.40 K
Value Traded
283.07 K
Short % Float
10.33%
-0.69%Week
+17.62%1 Month
+22.65%3 Month
+21.61%6 Month
-99.96%5 Year
-99.98%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
16.90 M
EPS (TTM)
-2.73
P/E Ratio
-
Ent. Value
6.98 M
Total Shares
11.78 M
Float Shares
11.08 M
Insiders
5.93%
Institutions
10.35%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
BNGO Catalyst Timeline
Dated clinical, regulatory and corporate events for Bionano Genomics, Inc.
Past FDA Catalysts and PDUFA Decisions
How BNGO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Bionano Genomics, Inc. is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every BNGO program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| T-cell acute lymphoblastic leukemia (T-ALL) | 2026-05-26 | detection rate ogm: 97.8%; detection rate karyotyping: 55%; additional genomic insights: 70%; known gene fusions: 24; novel gene fusions: 21; copy number changes: 93%; sequence variants ngs: 92%; notch1 variants: 57%Read More | Bionano Announces Largest OGM Study of T-Cell Acute Lymphoblastic LeukemiaRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Luderer AlbertDirector, Officer (Interim Chief Executive) | Buy | 4,000 8,000 held | $1.21 | 09/04/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BNGO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in BNGO for Q2 2026. | ||||
BNGO Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BNGO ranks across every disease it competes in
Competitive Position is a premium feature
See how BNGO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBNGO News
BNGO▼ -6.6%on this news
Bionano Laboratories Announces Expansion of Diagnostic Testing Based on Optical Genome Mapping for Hematologic Malignancies
Bionano Laboratories has announced the expansion of optical genome mapping (OGM) testing for hematologic malignancies at Memorial Sloan Kettering Cancer Center, following approval from the New York State Department of Health. This initiative represents a significant advancement in cancer diagnostics, enabling comprehensive genomic assessments that traditional methods struggle to achieve. The adoption of OGM by such a prestigious institution underscores its clinical value and potential for broader application.
Read more →BNGOBionano Laboratories Announces Proposed Local Coverage Determination (LCD) from MolDX for Genome-Wide Detection of Structural Variants in Hematologic Neoplasms
Bionano Laboratories announced a proposed Local Coverage Determination (LCD) from MolDX for genome-wide testing of structural variants in hematologic neoplasms. This proposed LCD aims to establish Medicare coverage for molecular testing, including optical genome mapping (OGM). The draft LCD is open for public comment until October 11, 2026, and recognizes the clinical validity of OGM compared to traditional methods.
Read more →BNGOBionano to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Bionano Genomics, Inc. announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference, scheduled for September 14, 2026. Management will present and host one-on-one meetings to engage with investors. A recording of the session will be available on the company's website for 90 days post-conference.
Read more →BNGOBionano to Report Second Quarter 2026 Financial Results and Host a Conference Call Webcast on August 10, 2026
Bionano Genomics, Inc. has announced a conference call and live webcast scheduled for August 10, 2026, at 4:30 p.m. Eastern Time. The call will cover the company's financial results for the second quarter of 2026 and discuss recent corporate developments. Investors can access the live event through the company's website.
Read more →BNGOBionano Announces Hiring of Chief Scientific Officer
Bionano Genomics has appointed Dr. Alex Hastie as Chief Scientific Officer, effective July 20, 2026. Dr. Hastie, a key figure in the company's technology development, will lead the scientific strategy and innovation roadmap. His return is positively received by the scientific community, who anticipate advancements in optical genome mapping and clinical applications.
Read more →BNGOBionano Announces 67% Year-Over-Year Growth in Studies Featuring Optical Genome Mapping at ESHG 2026, Reflecting Expanding Global Adoption
Bionano Genomics reported a 67% year-over-year increase in studies featuring optical genome mapping (OGM) at the 2026 ESHG conference. The growth reflects a broader global adoption of OGM, with contributions from 17 countries. Key research themes included rare genetic disorders and hematologic malignancies, highlighting OGM's potential in advancing cytogenomics.
Read more →BNGOBionano Announces Multiple Publications in 2026 Describing Unique Utility of OGM in Studies of Reproductive Health and Prenatal Genetic Disorders
Bionano Genomics announced the publication of 13 studies in 2026 highlighting the effectiveness of optical genome mapping (OGM) in reproductive health and prenatal genetic disorders. These studies, which involved 730 samples, demonstrated OGM's superior ability to detect and characterize structural variants compared to conventional methods like karyotyping. Key findings indicate that OGM outperformed traditional diagnostics in numerous cases, identifying previously undetectable genetic causes of infertility, miscarriages, and prenatal conditions. The breadth of research showcases OGM's significant role in advancing clinical genetic practices.
Read more →BNGOBionano Announces Full Retirement of Outstanding Senior Secured Convertible Debentures
Bionano Genomics has announced the complete retirement of its Senior Secured Convertible Debentures, originally valued at $20 million. This move, funded by cash on hand, eliminates all secured debt obligations, enhancing the company's financial flexibility. The chairman emphasized that this milestone allows Bionano to concentrate on growing its optical genome mapping business and executing its commercial strategy.
Read more →BNGOBionano Announces Largest OGM Study of T-Cell Acute Lymphoblastic Leukemia
Bionano Genomics announced a peer-reviewed study showing that optical genome mapping (OGM) significantly outperforms conventional cytogenetic methods in detecting genomic abnormalities in T-cell acute lymphoblastic leukemia (T-ALL). The study, conducted with 91 subjects, found a detection rate of 97.8% for OGM compared to 55% for traditional methods. This research highlights OGM's potential to enhance understanding and treatment of this aggressive cancer.
Read more →BNGOBionano Reports First Quarter 2026 Results and Provides a Business Update
Bionano Genomics reported its financial results for Q1 2026, revealing a 4% increase in total revenue, reaching $6.7 million. The company experienced strong growth in consumables revenue, which saw a 20% rise. Significant advancements were noted with newly implemented CPT codes enhancing reimbursement rates for OGM services. The company is also closing in on the retirement of secured convertible debt, which will bolster its financial stability for future investments.
Read more →BNGOBionano Announces Leadership Transition
Bionano Genomics has appointed Al Luderer as interim president and CEO, effective May 5, 2026. He succeeds Erik Holmlin, who remains as an advisor. Luderer, with over 30 years in biotechnology, aims to ensure a smooth transition and continue the company's growth. The board expresses confidence in his leadership during this period.
Read more →BNGOBionano Announces a 56% Increase in Publications Describing the Utility of OGM in Rare Diseases in Q1 2026 vs Q1 2025
Bionano Genomics reported a 56% increase in publications related to optical genome mapping (OGM) for rare diseases in Q1 2026 compared to Q1 2025. The findings reveal that OGM significantly enhances the identification and characterization of structural variants, often missed by traditional methods. A total of 28 publications were analyzed, reflecting a substantial growth in the use of OGM across various global institutions. The studies collectively emphasized OGM's role in resolving previously unexplained rare disease cases and its potential as a gold standard technique for genomic analysis.
Read more →BNGOBionano to Report First Quarter 2026 Financial Results and Host a Conference Call Webcast on May 13, 2026
Bionano Genomics, Inc. has announced a conference call and webcast scheduled for May 13, 2026, at 4:30 p.m. ET to discuss its first quarter 2026 financial results. The event will also cover recent corporate developments. Participants can access the live webcast through the company's investor relations page.
Read more →BNGOBionano Announces Publication from Johns Hopkins and MD Anderson Showing that OGM can Outperform Traditional Methods in Analysis of Multiple Myeloma
Bionano Genomics announced a study showing that optical genome mapping (OGM) outperforms traditional methods in analyzing multiple myeloma. The multicenter research, published in the American Journal of Hematology, demonstrated OGM's higher success rates in detecting chromosomal abnormalities and its ability to identify additional pathogenic findings. The study supports the integration of OGM into standard laboratory workflows for better genomic profiling.
Read more →BNGO▼ -19.2%on this news
Bionano Reports Fourth Quarter and Full-Year 2025 Results and Provides Revenue Outlook for 2026
Bionano Genomics reported its financial results for Q4 and the full year 2025, highlighting significant growth in optical genome mapping utilization. The company anticipates continued momentum into 2026, bolstered by increased payment rates for OGM services and strong engagement from the global OGM community. CEO Erik Holmlin expressed optimism about the future of OGM in clinical applications.
Read more →BNGOBionano Announces Two-Fold Increase in OGM Studies Presented at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
Bionano Genomics announced a significant increase in the studies presented at the 2026 ACMG Annual Meeting, where twelve studies focused on the application of optical genome mapping (OGM) in detecting structural variants. This marks a two-fold increase compared to previous years, illustrating the technique's growing relevance in cancer genomics and genetic disorders. Attendees engaged in workshops to learn about OGM applications from experts, while Baylor Genetics launched a new service to enhance research accessibility to OGM data. Despite the positives, the announcement also contains forward-looking statements that come with uncertainties affecting future performance.
Read more →BNGOBionano to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call Webcast on March 23, 2026
Bionano Genomics, Inc. has announced a conference call and live webcast scheduled for March 23, 2026, at 4:30 p.m. Eastern Time. The purpose of this event is to report the financial results for the fourth quarter and full year of 2025, as well as to highlight recent corporate progress. Participants can access the live webcast through the Bionano Investors page, and a replay will be available for 30 days.
Read more →BNGOBionano Symposium 2026 Concluded with 9 Speakers Describing the Breadth of Bionano Solutions and Their Potential for Use on a Large Scale
Bionano Genomics concluded Symposium 2026, highlighting advancements in optical genome mapping (OGM) and its applications in cytogenetics and molecular pathology. Over 1,250 attendees participated, with presentations from leading laboratories discussing automation and scalability of OGM. Key speakers emphasized the transformative potential of OGM in research and clinical settings, showcasing innovations that enhance genome analysis.
Read more →BNGO10 Presentations on Day 3 of Bionano Symposium 2026 Showcase OGM’s Utility in Unraveling the Complex Puzzles of Constitutional Genetic Disorders
Bionano Genomics showcased the utility of optical genome mapping (OGM) in addressing complex constitutional genetic disorders during Day 3 of its 2026 Symposium. Presentations from global experts illustrated OGM's ability to detect previously undetectable genetic variants and structural rearrangements, emphasizing its transformative role in genetic research. The event attracted over 1,200 participants, reflecting a growing interest in OGM applications.
Read more →BNGO11 Presentations on Day 2 of Bionano Symposium 2026 Showcase Expanding Impact of Optical Genome Mapping Across Oncology and Cell & Gene Therapy
Bionano Genomics showcased advancements in Optical Genome Mapping (OGM) at Symposium 2026, emphasizing its role in oncology and cell therapy. Presentations highlighted OGM's ability to detect structural variants in cancers, including rare types. The event saw significant participation, indicating growing interest in OGM's applications in genomic research and therapeutic innovation.
Read more →About Bionano Genomics, Inc.
Headquarters9540 TOWNE CENTRE DRIVE, SAN DIEGO, CA, 92121
BIOPHARMAWATCH ELITE PLUS
Trade the next BNGO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime